Sanjiu Pharmaceutical’s mission and vision:
Care for public health, focus on drug manufacturing, build a trustworthy brand, and build Sanjiu Pharmaceutical into a listed company that maximizes shareholder value and employee value . As one of the largest comprehensive pharmaceutical companies in my country, Sanjiu Pharmaceutical Co., Ltd. is mainly engaged in the development, production, sales of drugs and corresponding medical and health services. The company's existing varieties are mainly Chinese patent medicines, and involve chemical raw materials and preparations, biological products, medical and health materials and other pharmaceutical fields. Our products radiate across the country and around the world, selling well in Japan, the United States, Canada, South Korea and Southeast Asia, and we have established stable trade relations with many foreign companies. Sanjiu Medicine owns a number of nationally renowned brand-name products such as Sanjiu Weitai series, Sanjiu Ganmaoling series, Sanjiu Piyanping ointment, and Shenmai injection. Its main products rank among the top of similar products in domestic market share, among which Some are still in the absolute leading position. As of December 31, 2003, Sanjiu Pharmaceutical Co., Ltd.'s total assets reached 8.296 billion yuan. In 2003, it achieved main business income of 2.674 billion yuan and net profit of 209 million yuan.
The development goals of Sanjiu Medicine are: taking science and technology as the guide, taking "modernization of traditional Chinese medicine" as the core, taking into account the development of Western medicine and medical and health services, and striving to make Sanjiu Medicine a center of R&D and production of pharmaceuticals and Western medicines. and sales and healthcare services. Sanjiu Enterprise Group focuses on the pharmaceutical business and has pursued the business philosophy of high technology, high quality and high efficiency since its inception. Working hard and serving the country through industry have become the business philosophy and entrepreneurial spirit of Sanjiu Group. Run the enterprise with first-class talents, engage in production with first-class equipment, provide first-class products to users, and contribute first-class services to society. It has sales offices and warehouses in 15 provinces and 4 municipalities across the country, forming a nationwide pharmaceutical sales network; it has established professional sales departments for antibiotics, traditional Chinese medicine injections, biological products, health products, and medical devices.
Sanjiu Enterprise Group conducts technology development work in a manner that combines industry, academia, and research; the Group Pharmaceutical Research Institute is overall responsible for the strategic direction of the group's technology development, and each enterprise sets up corresponding specialized research according to its professional direction. Each institute has extensive cooperation with major domestic universities and research institutions. The established research institutes include Sanjiu Bioengineering Research Institute, Sanjiu West China Traditional Chinese Medicine Injection Research Institute, Sanjiu Antibiotic Research Institute, Sanjiu Chinese Patent Medicine Research Institute, etc. The State-owned Assets Supervision and Administration Commission selected China Resources Group as a strategic investor and implemented the capital restructuring of Sanjiu Enterprise Group after approval by the State Council.
The relevant person in charge of the State-owned Assets Supervision and Administration Commission said that the preliminary selection of strategic investors introduced by Sanjiu Group will be conducive to solving the debt crisis of Sanjiu Group and the problem of occupying funds of listed companies as soon as possible, and will be conducive to effectively safeguarding listed companies. The rights and interests of small and medium-sized shareholders are conducive to minimizing losses in all aspects and promoting the healthy development of enterprises. Sanjiu Enterprise Group is a large state-owned pharmaceutical enterprise directly managed by the State-owned Assets Supervision and Administration Commission. It owns the listed company "Sanjiu Pharmaceutical" and a number of pharmaceutical manufacturers that have passed GMP certification, involving pharmaceutical manufacturing, pharmaceutical packaging, pharmaceutical sales, medical services and other fields. Nearly a thousand Chinese and Western medicine products and a nationwide pharmaceutical sales network. The "999" pharmaceutical brand has great influence at home and abroad.
In December 2006, according to the debt restructuring framework plan negotiated with the Sanjiu Creditors Committee, in order to ensure the smooth transition and long-term development of the company, in accordance with the principles of overall restructuring and market-oriented operation, the introduction of strategic investors was implemented Work. According to reports, the State-owned Assets Supervision and Administration Commission carefully studied the plans submitted by each group of strategic investors on the basis of expert voting and review, and selected China Resources Group as the strategic investor. The court found that in early 1996, Hong Kong Chang Teng (China) Investment Co., Ltd. established Shenzhen Seaview Golf Resort Co., Ltd., which was actually 100% controlled by Hong Kong Chang Teng Company. It was specifically responsible for the construction of 7.64 square kilometers in Maluan Village, Pingshan Town, Longgang District. Golf course and supporting facilities projects. In October 1999, Lin Qingqu, chairman of Changteng Company (handled in another case), was introduced by a friend to the defendant Chen Dacheng, who was then the general manager of Hong Kong Sanjiu Automobile Co., Ltd., a subsidiary of Sanjiu Enterprise Group. Chen learned that Lin owned the Meisha Golf Course Project Later, he reported to Zhao Xinxian, the then general manager of Sanjiu Enterprise Group, who instructed Chen to negotiate with Lin on behalf of Sanjiu Enterprise Group to acquire the project. Since then, Zhao and Chen have negotiated acquisitions with Lin Qingqu many times and reached an intention to acquire them.
In February 2000, when the acquisition project had not been formally evaluated, studied by the Sanjiu Enterprise Group Party Committee, and submitted to the State Planning Commission and relevant departments for approval as required, Zhao Xinxian represented the company without authorization and negotiated with Lin Qingqu An "Equity Acquisition Agreement" was signed in Hong Kong, stipulating that Hong Kong Sanjiu Industrial Company, a subsidiary of Sanjiu Enterprise Group, will acquire 80% of the equity of Hong Kong Changteng Company and 80% of the equity of Seaview Golf Company from Lin Qingqu. The acquisition price is HK$4.7 billion, to be paid in two installments. Afterwards, Zhao Xinxian and others forged the "Minutes of the Board of Directors Meeting of Hong Kong Sanjiu Industrial Co., Ltd. held at its registered address". Zhao Xinxian, the then director of Hong Kong Sanjiu Industrial Co., Ltd., the defendant Rong Longzhang and the then Sanjiu Pharmaceutical Company The defendants, the Minister of Finance and the Chief Accountant, signed the meeting minutes to confirm that the fictitious board meeting discussed and approved the above-mentioned acquisition.
Because Hong Kong Sanjiu Industrial Co., Ltd. did not have the ability to pay, Zhao Xinxian instructed Chen Dacheng and Rong Longzhang to organize the raising and payment of the acquisition funds.
It was proposed to pay the acquisition amount of 470 million yuan in the form of applying for bank loans and shareholder dividends, and reported to Zhao Xinxian for approval. Subsequently, Sanjiu Pharmaceutical Company pledged a RMB 230 million deposit at Shenzhen CITIC Bank and obtained a Hong Kong dollar loan of 200 million from CITIC Ka Wah Bank, which was paid directly to Lin Qingqu as the first installment of the equity acquisition. After the above-mentioned loan matures, Sanjiu Pharmaceutical Company will use the pledged deposits to repay the loan debt of Hong Kong Sanjiu Automobile Co., Ltd.
On May 29 of the same year, Zhao Xinxian also instructed Chen Dacheng, Rong Longzhang and others to inflate the amount of dividends, and forged the "Shenzhen Sanjiu Pharmaceutical Co., Ltd. Board of Directors' Decision on the Distribution of Rollover Profit in 1999" Resolution, signed and confirmed by Zhao Xinxian, Rong Longzhang and others, fictitiously paid RMB 292.6 million to Hong Kong Sanjiu Company in the name of dividends. Based on this, he fraudulently purchased foreign exchange from the national foreign exchange administration agency and relevant banks, totaling US$35.3 million, and remitted it to Hong Kong Guang'an Bank. In June of the same year, Hong Kong Sanjiu Company issued a draft of HK$270 million for the amount, which was delivered to Lin Qingqu as the second installment of the equity acquisition. After the completion of the above-mentioned acquisition, Sanjiu Enterprise Group changed the name of "Shenzhen Seaview Golf Resort Co., Ltd." to "Sanjiu Dalong Health City Co., Ltd." Since the land use right certificate was not obtained before and after the acquisition, the government approval documents obtained before the project acquisition They are all planning and planning in nature and do not yet have the conditions for development and operation. This project is still at a standstill. When Sanjiu Enterprise Group liquidated its assets and capital in 2004, it reported the full amount of HK$470 million used to acquire 80% of the equity of Hong Kong Changteng Investment Company to the State-owned Assets Supervision and Administration Commission for approval as a loss write-off.
The court held that the above-mentioned defendant’s behavior constituted the crime of abuse of power. In view of the fact that the defendant could truthfully confess the crime facts after being brought to justice, and his subjective malignity was small, the court made the above judgment. None of the defendants appealed and the case is now legally binding.